Skip to main content
. 2017 Apr 7;8(24):38568–38580. doi: 10.18632/oncotarget.16930

Figure 4. Analysis of binding ability of rE/CUS to tumor cell lines by Flow cytometry.

Figure 4

EGFR-positive cell lines HepG2, A549, SW116 and EGFR negative cell line SW620 were treated with 7D12 and rE/CUS. Cells were incubated with mouse anti-HIS antibody and the mouse anti-HIS-APC, then analyzed by Flow cytometry.